Assignee
IDORSIA PHARMACEUTICALS LTD
SE·77 granted patents·30 pending applications·138 citations·filing 2013–2025
Top patents by PatentIndex Score
107 records- 0196US11680058B2Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentanIDORSIA PHARMACEUTICALS LTD·Filed 2021·Granted Jun 20, 2023·5 cites·21 claims
- 0293US11787782B2Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseasesIDORSIA PHARMACEUTICALS LTD·Filed 2021·Granted Oct 17, 2023·5 cites·39 claims
- 0392US12011444B2N-substituted indole derivatives as PGE2 receptor modulatorsIDORSIA PHARMACEUTICALS LTD·Filed 2021·Granted Jun 18, 2024·2 cites·23 claims
- 0491US10385043B2Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diolIDORSIA PHARMACEUTICALS LTD·Filed 2016·Granted Aug 20, 2019·4 cites·9 claims
- 0590US11446298B2Pyrimidine derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2018·Granted Sep 20, 2022·5 cites·20 claims
- 0689US11325899B2Benzofurane and benzothiophene derivatives as PGE2 receptor modulatorsIDORSIA PHARMACEUTICALS LTD·Filed 2018·Granted May 10, 2022·6 cites·33 claims
- 0789US10919881B2Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentanIDORSIA PHARMACEUTICALS LTD·Filed 2018·Granted Feb 16, 2021·10 cites·24 claims
- 0887US11174247B2Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseasesIDORSIA PHARMACEUTICALS LTD·Filed 2017·Granted Nov 16, 2021·6 cites·47 claims
- 0987US9732075B2Benzimidazole-proline derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2013·Granted Aug 15, 2017·8 cites·12 claims
- 1086US11390615B2Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxIDORSIA PHARMACEUTICALS LTD·Filed 2020·Granted Jul 19, 2022·1 cites·19 claims
- 1186US11059803B2Crystalline form of N-[1-(5-cyano-pyridin-2- ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamideIDORSIA PHARMACEUTICALS LTD·Filed 2018·Granted Jul 13, 2021·2 cites·12 claims
- 1285US10836754B2Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diolIDORSIA PHARMACEUTICALS LTD·Filed 2019·Granted Nov 17, 2020·1 cites·33 claims
- 1385US10065929B2Pyrazole compounds and their use as T-type calcium channel blockersIDORSIA PHARMACEUTICALS LTD·Filed 2017·Granted Sep 4, 2018·5 cites·30 claims
- 1484US12297189B2Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentanIDORSIA PHARMACEUTICALS LTD·Filed 2023·Granted May 13, 2025·0 cites·25 claims
- 1584US11712438B2Phenyl derivatives as PGE2 receptor modulatorsIDORSIA PHARMACEUTICALS LTD·Filed 2018·Granted Aug 1, 2023·2 cites·22 claims
- 1684US11241431B2N-substituted indole derivatives as PGE2 receptor modulatorsIDORSIA PHARMACEUTICALS LTD·Filed 2016·Granted Feb 8, 2022·6 cites·21 claims
- 1784US10329287B2Benzimidazole-proline derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2017·Granted Jun 25, 2019·3 cites·12 claims
- 1884US9932314B2Pyrazole compounds and their use as T-type calcium channel blockersIDORSIA PHARMACEUTICALS LTD·Filed 2015·Granted Apr 3, 2018·5 cites·28 claims
- 1983US11365209B2Crystalline formsIDORSIA PHARMACEUTICALS LTD·Filed 2020·Granted Jun 21, 2022·1 cites·46 claims
- 2083US10023560B2Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonistIDORSIA PHARMACEUTICALS LTD·Filed 2017·Granted Jul 17, 2018·3 cites·13 claims
- 2183US9938244B2Process for manufacturing pyrimidine sulfamide derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2015·Granted Apr 10, 2018·7 cites·21 claims
- 2283US9850256B2Antibacterial basic biaromatic derivatives with aminoalkoxy substitutionIDORSIA PHARMACEUTICALS LTD·Filed 2015·Granted Dec 26, 2017·4 cites·15 claims
- 2382US12344597B2Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosisIDORSIA PHARMACEUTICALS LTD·Filed 2019·Granted Jul 1, 2025·2 cites·21 claims
- 2482US10246426B2Triazole compounds as T-type calcium channel blockersIDORSIA PHARMACEUTICALS LTD·Filed 2015·Granted Apr 2, 2019·5 cites·13 claims
- 2581US9790208B2Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonistIDORSIA PHARMACEUTICALS LTD·Filed 2014·Granted Oct 17, 2017·4 cites·6 claims
- 2680US11479574B2Vaccine against Klebsiella pneumoniaeIDORSIA PHARMACEUTICALS LTD·Filed 2018·Granted Oct 25, 2022·2 cites·40 claims
- 2780US10730896B2Crystalline formsIDORSIA PHARMACEUTICALS LTD·Filed 2017·Granted Aug 4, 2020·1 cites·16 claims
- 2879US11834443B2Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diolIDORSIA PHARMACEUTICALS LTD·Filed 2022·Granted Dec 5, 2023·0 cites·26 claims
- 2978US12144811B2Combination of a 4-pyrimidinesulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin related diseasesIDORSIA PHARMACEUTICALS LTD·Filed 2018·Granted Nov 19, 2024·1 cites·31 claims
- 3078US11839613B2Pyrimidine derivatives as PGE2 receptor modulatorsIDORSIA PHARMACEUTICALS LTD·Filed 2018·Granted Dec 12, 2023·1 cites·20 claims
- 3178US9914720B2Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonistsIDORSIA PHARMACEUTICALS LTD·Filed 2014·Granted Mar 13, 2018·3 cites·12 claims
- 3278US9914721B2Use of benzimidazole-proline derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2014·Granted Mar 13, 2018·4 cites·14 claims
- 3376US10314823B2Substituted 1,2-dihydro-3H-pyrrolo[1,2-c]imidazol-3-one antibacterial compoundsIDORSIA PHARMACEUTICALS LTD·Filed 2016·Granted Jun 11, 2019·5 cites·39 claims
- 3476US9879006B2Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulatorsIDORSIA PHARMACEUTICALS LTD·Filed 2015·Granted Jan 30, 2018·2 cites·29 claims
- 3574US11267824B2Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenaseIDORSIA PHARMACEUTICALS LTD·Filed 2018·Granted Mar 8, 2022·1 cites·14 claims
- 3674US9796686B2Antibacterial quinazoline-4(3H)-one derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2015·Granted Oct 24, 2017·3 cites·15 claims
- 3773US10899695B2Process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanesIDORSIA PHARMACEUTICALS LTD·Filed 2018·Granted Jan 26, 2021·1 cites·17 claims
- 3873US10202368B2CXCR7 receptor modulatorsIDORSIA PHARMACEUTICALS LTD·Filed 2015·Granted Feb 12, 2019·2 cites·16 claims
- 3972US9822114B2Tricyclic oxazolidinone antibiotic compoundsIDORSIA PHARMACEUTICALS LTD·Filed 2016·Granted Nov 21, 2017·1 cites·17 claims
- 4072US9802901B2Antibacterial 2H-indazole derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2014·Granted Oct 31, 2017·2 cites·16 claims
- 4172US2025257056A1Alpha-d-galactopyranoside derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2025·Application pending·0 cites
- 4271US11040966B2Benzimidazole-proline derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2019·Granted Jun 22, 2021·0 cites·29 claims
- 4371US2025120973A1Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseasesIDORSIA PHARMACEUTICALS LTD·Filed 2024·Application pending·0 cites
- 4470US2023165859A1N-substituted indole derivativesIDORSIA PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 4569US11891413B2Vaccine against Klebsiella pneumoniaeIDORSIA PHARMACEUTICALS LTD·Filed 2018·Granted Feb 6, 2024·1 cites·32 claims
- 4669US11555025B2Crystalline form of N-[1-(5-cyano-pyridin-2-ylmethyl)-1 H-pyrazol-3-yl]-2- [4-(1-trifluoromethyl-cyclopropyl)-phenyl-acetamideIDORSIA PHARMACEUTICALS LTD·Filed 2021·Granted Jan 17, 2023·0 cites·2 claims
- 4769US10047080B2(R)-2-methyl-piperazine derivatives as CXCR3 receptor modulatorsIDORSIA PHARMACEUTICALS LTD·Filed 2016·Granted Aug 14, 2018·1 cites·14 claims
- 4869US9920010B2CXCR7 receptor modulatorsIDORSIA PHARMACEUTICALS LTD·Filed 2014·Granted Mar 20, 2018·2 cites·36 claims
- 4968US10441576B2Substituted 1,2-dihydro-3H pyrrolo[1,2-c]imidazol-3 one antibacterialsIDORSIA PHARMACEUTICALS LTD·Filed 2016·Granted Oct 15, 2019·1 cites·16 claims
- 5068US2023192708A12,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds as c5a receptor modulators for treating vasculitis and inflammatory diseasesIDORSIA PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
Showing the top 50 of 107 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when IDORSIA PHARMACEUTICALS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →